Ö×ÁöÇÖ·¸,Neoplasm invasivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ­»·Ö×Áöϸ°û,Circulating tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« °ÚλÎó²î,setup errorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼äÖÊ»¯ÁÆ,interstitial chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×éÃâÒ߶¾ËØ,Recombinant ImmunotoxinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« mdm2»ùÒò,mdm2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ԭʼÉñ¾­ÍâÅß²ãÖ×Áö,Primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ±íÐÍ,malignant phenotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²îÒì¶È,difference degreeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Egr-1Æô¶¯×Ó,Egr-1 promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Á¬ÐøÄ£ÐÍ,continuous modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÎÏÙ°©,lung adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« תÒÆ°©,Metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔ¼äƤÁö,Malignant mesotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´Êý´Åµ¼ÂÊ,complex permeabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« θ°©Ï¸°û,Gastric cancer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÖÖÖ²,neoplasm seedingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼××´ÏÙת¼Òò×Ó-1,thyroid transcription factor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Òò¹û·ÖÎö,causal analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« hTERTÆô¶¯×Ó,hTERT promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇתÒÆÁö,bone metastasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶àÔ­·¢°©,Multiple Primary CarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÒÊæ×¢ÉäÒº,Yanshu injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÂÁ¢ÐÔÏËάÐÔÖ×Áö,Solitary fibrous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß¼¶Ö¬·¾Ëá,higher fatty acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·Ç²ÎÊý»Ø¹é,Nonparametric regressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ´×Ëá¼×µØÔÐͪ,megestrol acetateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÛ״ϸ°û°©¿¹Ô­,Squamous cell carcinoma antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×éÈËÄÚƤÒÖËØ,Recombinant human endostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏúÊÛ½ð¶î,Consumption sumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ­ÄÔÕÕÉä,Cranial irradiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« B16ºÚÉ«ËØÁö,B16 melanomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼î»ùÇгýÐÞ¸´,Base excision repairÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÌÓÒÝ,Tumor escapeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ˳²¬/ͶҩºÍ¼ÁÁ¿,cisplatin/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏƤÑùѪ¹ÜÄÚƤÁö,epithelioid hemangioendotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÏ֪ϵͳ,Cognitive systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÐØÜÕËáºÏø,Thymidylate synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½ºÍÓÂÝ,Bulgaria inquinansÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄæÏò¼Æ»®,inverse planningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶ñÐÔÐÄ°ü»ýÒº,malignant pericardial effusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« RNA¾ÛºÏø¢ò,RNA polymerase ¢òÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« DNAÍ»±ä,DNA mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÚÏãÌÇ,chewing gumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏƤÑùÈâÁö,Epithelioid sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ÷Ç¿·ÅÉäÖÎÁÆ,IMRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ý¼ÌÐÔÃâÒßÖÎÁÆ,Adoptive immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿ÅÁ£Ï¸°ûÁö,Granular cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±´Ò¶Ë¹¶¨Àí,Bayes theoremÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏßÐÔÏìÓ¦,Linear responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßÇ¿¶È¾Û½¹³¬Éù(HIFU),high intensity focused ultrasound (HIFU)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ERCC1»ùÒò,ERCC1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÅßñ¼Áö,Endodermal sinus tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÄÚ·ÖÃÚÖ×Áö,Neuroendocrine tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« WWOX»ùÒò,WWOX geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÎËáÅÁÂåŵ˾Çí,palonosetron hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éñ¾­ÏµÍ³Ö×Áö,nervous system neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚƤÉú³¤Òò×Ó/ÉúÎïºÏ³É,endothelial growth factors/biosynthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÅàÃÀÇúÈû¶þÄÆ,Pemetrexed disodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ºÊÍ×÷ÓÃ,sustained releaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Í黯¼Á,Alkylating agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ̼·ÅÉäÐÔͬλËØ,Carbon radioisotopesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉúͪÒûʳ,Ketogenic dietÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö½þÈóÁÜ°Íϸ°û,tumor infiltrating lymphocytesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸´¶û¿µ×¢ÉäÒº,Fuerkang injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯ÁÆÄÍÒ©,ChemoresistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¯ÁÆÏà¹ØÐÔ¸¹Ðº,chemotherapy-induced diarrheaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö¼ì²â,tumor detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÜ°ÍÒýÁ÷,Lymphatic drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×Áö/ÖÐÒ©ÁÆ·¨,NEOPLASMS/TCD therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« E6µ°°×,E6 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ¾úDNA,Bacterial DNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×éÈËѪ¹ÜÄÚƤÒÖÖÆËØ/¶÷¶È,Recombinant human endostatin/EndostarÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ¡ÔñÔ­Ôò,selection principleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HedgehogÐźÅͨ·,hedgehog signaling pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÐÝÃß,Tumor dormancyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÎÁƼƻ®,treatment planningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö×ÁöÒ׸ÐÐÔ,tumor susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹Ç»¯ÐÔÏËάÁö,Ossifying fibromaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« AskinÁö,Askin tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ôÊ»ùÌú·Û,carbonyl iron powderÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Â-é­ÏãÏ©ÑÜÉúÎï,¦Â-elemene derivativesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑéÖ¤·½·¨,verification methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒþÐÎÄÉÃ×Á£,stealth nanoparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ȱÑõ»·¾³,anoxic environmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÖ°©»ùÒòp53,tumor suppressor gene p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ïνӵ°°×ÖÊÀà,Adaptor ProteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏƤÐÔÖ×Áö,Epithelial tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÖÊÖØËÜ,Matrix remodelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô­·¢Ôî,primary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¯Âö¹à×¢»¯ÁÆ,intra-arterial infusion chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²Ö×Áöѧ,Clinical oncologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿¹Ñõ»¯·´Ó¦Ôª¼þ,antioxidant response elementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« WntÐźÅתµ¼Í¨Â·,Wnt signaling pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈËÎÄ¿Æѧ,HumanitiesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚÅß²ãñ¼Áö,endodermal sinus tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖØ×é¸Ä¹¹ÈËÖ×Áö»µËÀÒò×Ó,recombinant mutant human tumor necrosis factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÃÏ¢ÐÔÊÖÊõ,palliative operationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ùÖʽðÊôµ°°×ø-26,Matrix metalloproteinase-26Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Damiϸ°û,Dami cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 3 4 5 6 7 8 9 10 ÉÏÒ»Ò³